2018, 2017, 2016, 2015, 2014, 2013
JULY – SEPTEMBER · Net sales amounted to MSEK 443.7 (395.3). This corresponds to an increase of 12% for the period, of which the acquired operations account for 10% (MSEK 41.0). · Adjusted EBITDA amounted to MSEK 156.9 (145.8) excluding non-recurring items, costs related to the acquisition of Trimb and restructuring costs totalling MSEK 28.2....
Read moreTHE PERIOD AND THE SECOND QUARTER
Read more· Net sales amounted to MSEK 420.8 (267.1). This corresponds to an increase of 58%. The growth is attributable to products acquired during the period. · Net sales decreased by 6% compared to pro forma numbers for the same period 2018. At comparable exchange rates, sales decreased by 8%. The decrease in net sales is...
Read moreKaro Pharma publishes its annual report for 2018. Today, on 9 April 2019, Karo Pharma is publishing its annual report for 2018 on the company’s website, www.karopharma.com (http://%20www.karopharma.com). FOR ADDITIONAL INFORMATION, PLEASE CONTACT: Mats-Olof Wallin, CFO, +4676 002 60 10, mats-olof.wallin@karopharma.se ABOUT KARO PHARMA Karo Pharma is a Specialty Pharma company, which develops and markets products for pharmacies...
Read moreFULL YEAR AND THE FOURTH QUARTER · Net sales amounted to MSEK 1,615.1 (657.6), of which the fourth quarter amounted to MSEK 463.3 (238.7). This corresponds to an increase of 146% for the full year, and 94% for the fourth quarter. A large part of the growth is attributable to products acquired during the period....
Read more